{"entity":"regeneron-pharmaceuticals","id":"ent_regeneron-pharmaceuticals","name":"Regeneron Pharmaceuticals","from":"2025-11-09","to":"2026-11-09","page":"https://asof.is/record/regeneron-pharmaceuticals/diff?from=2025-11-09&to=2026-11-09","summary":"Between 2025-11-09 and 2026-11-09, Regeneron Pharmaceuticals's record changed in 19 facts: 4 replaced (net income $4.41 billion → $4.5 billion; operating income $3.99 billion → $3.58 billion; research and development $5.13 billion → $5.85 billion and 1 more), 8 added, 7 ended; 11 unchanged.","counts":{"changed":19,"added":8,"ended":7,"replaced":4,"unchanged":11,"skipped_posts":{"from":0,"to":0}},"by_predicate":[{"predicate":"cash_and_equivalents","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_net_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_operating_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_research_and_development","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_revenue","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_assets","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_equity","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"agreement","added":1,"ended":0,"replaced":0,"unchanged":0},{"predicate":"net_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"operating_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"research_and_development","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"revenue","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"ceo","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"cfo","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"cik","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"fiscal_year_end","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"headquarters","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"listed_on","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"registrant_name","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"shares_outstanding","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"sic_industry","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"state_of_incorporation","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"ticker","added":0,"ended":0,"replaced":0,"unchanged":1}],"added":[{"id":"clm_630C3A822A55","predicate":"agreement","value":"Sanofi","valid_from":"2026-10-01","valid_to":null,"published":"2026-10-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals agreement: Sanofi\", as of 2026-10-01. Claim clm_630C3A822A55, https://asof.is/claim/clm_630C3A822A55, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/0001104659-26-113895-index.htm.","url":"https://asof.is/claim/clm_630C3A822A55","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/0001104659-26-113895-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K","published_at":"2026-10-06T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“ Regeneron ” or the “ Company ”), Sanofi Biotechnology SAS,","url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926113895/0001104659-26-113895-index.htm"}},{"id":"clm_5EBA4C72A92F","predicate":"cash_and_equivalents","value":"3,659,100,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 3,659,100,000 United States dollar\", as of 2026-09-30. Claim clm_5EBA4C72A92F, https://asof.is/claim/clm_5EBA4C72A92F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_5EBA4C72A92F","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_DEF587D6916A","predicate":"quarterly_net_income","value":"1,948,700,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,948,700,000 United States dollar\", as of 2026-09-30. Claim clm_DEF587D6916A, https://asof.is/claim/clm_DEF587D6916A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_DEF587D6916A","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_4585DB96888D","predicate":"quarterly_operating_income","value":"2,048,200,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 2,048,200,000 United States dollar\", as of 2026-09-30. Claim clm_4585DB96888D, https://asof.is/claim/clm_4585DB96888D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_4585DB96888D","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_4D8C13296D0A","predicate":"quarterly_research_and_development","value":"1,794,700,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,794,700,000 United States dollar\", as of 2026-09-30. Claim clm_4D8C13296D0A, https://asof.is/claim/clm_4D8C13296D0A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_4D8C13296D0A","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_15BDC7B1496E","predicate":"quarterly_revenue","value":"5,115,800,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 5,115,800,000 United States dollar\", as of 2026-09-30. Claim clm_15BDC7B1496E, https://asof.is/claim/clm_15BDC7B1496E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_15BDC7B1496E","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_F46BE3EF6472","predicate":"total_assets","value":"44,405,200,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 44,405,200,000 United States dollar\", as of 2026-09-30. Claim clm_F46BE3EF6472, https://asof.is/claim/clm_F46BE3EF6472, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_F46BE3EF6472","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_24A29A7153C0","predicate":"total_equity","value":"33,498,500,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 33,498,500,000 United States dollar\", as of 2026-09-30. Claim clm_24A29A7153C0, https://asof.is/claim/clm_24A29A7153C0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm.","url":"https://asof.is/claim/clm_24A29A7153C0","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000034/0000872589-26-000034-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-10-30"}}],"ended":[{"id":"clm_5CC511D1F933","predicate":"cash_and_equivalents","value":"2,506,400,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals cash and equivalents: 2,506,400,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_5CC511D1F933, https://asof.is/claim/clm_5CC511D1F933, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_5CC511D1F933","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B18C1963BC40","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_75B9586D5FEE","predicate":"quarterly_net_income","value":"1,460,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly net income: 1,460,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_75B9586D5FEE, https://asof.is/claim/clm_75B9586D5FEE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_75B9586D5FEE","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_55728063B1D6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_0F41A2F44A01","predicate":"quarterly_operating_income","value":"1,026,800,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,026,800,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_0F41A2F44A01, https://asof.is/claim/clm_0F41A2F44A01, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_0F41A2F44A01","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6BF4C3658A74","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_F00F9DA4362C","predicate":"quarterly_research_and_development","value":"1,475,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly research and development: 1,475,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_F00F9DA4362C, https://asof.is/claim/clm_F00F9DA4362C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_F00F9DA4362C","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D76E4D0088C5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_471EC2DBAE0B","predicate":"quarterly_revenue","value":"3,754,300,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly revenue: 3,754,300,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_471EC2DBAE0B, https://asof.is/claim/clm_471EC2DBAE0B, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_471EC2DBAE0B","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_89291214D4AA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_A47C41C5A48C","predicate":"total_assets","value":"40,169,400,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 40,169,400,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_A47C41C5A48C, https://asof.is/claim/clm_A47C41C5A48C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_A47C41C5A48C","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CFD74D844717","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-10-28"}},{"id":"clm_CF9BA729AF1E","predicate":"total_equity","value":"30,957,800,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total equity: 30,957,800,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_CF9BA729AF1E, https://asof.is/claim/clm_CF9BA729AF1E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm.","url":"https://asof.is/claim/clm_CF9BA729AF1E","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_68C522C0BDED","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/0000872589-25-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-10-28"}}],"replaced":[{"predicate":"net_income","from":{"id":"clm_4E27594C511A","predicate":"net_income","value":"4,412,600,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 4,412,600,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_4E27594C511A, https://asof.is/claim/clm_4E27594C511A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_4E27594C511A","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7514724ED5E9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-05"}},"to":{"id":"clm_7514724ED5E9","predicate":"net_income","value":"4,504,900,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals net income: 4,504,900,000 United States dollar\", as of 2025-12-31. Claim clm_7514724ED5E9, https://asof.is/claim/clm_7514724ED5E9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_7514724ED5E9","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-04"}}},{"predicate":"operating_income","from":{"id":"clm_398CD3D76930","predicate":"operating_income","value":"3,990,700,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 3,990,700,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_398CD3D76930, https://asof.is/claim/clm_398CD3D76930, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_398CD3D76930","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1B456AFB0CC5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-05"}},"to":{"id":"clm_1B456AFB0CC5","predicate":"operating_income","value":"3,577,900,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals operating income: 3,577,900,000 United States dollar\", as of 2025-12-31. Claim clm_1B456AFB0CC5, https://asof.is/claim/clm_1B456AFB0CC5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_1B456AFB0CC5","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-04"}}},{"predicate":"research_and_development","from":{"id":"clm_C301E7CAF361","predicate":"research_and_development","value":"5,132,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 5,132,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_C301E7CAF361, https://asof.is/claim/clm_C301E7CAF361, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_C301E7CAF361","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1819F20C7CC4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2024, filed 2025-02-05"}},"to":{"id":"clm_1819F20C7CC4","predicate":"research_and_development","value":"5,850,200,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals research and development: 5,850,200,000 United States dollar\", as of 2025-12-31. Claim clm_1819F20C7CC4, https://asof.is/claim/clm_1819F20C7CC4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_1819F20C7CC4","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2025, filed 2026-02-04"}}},{"predicate":"revenue","from":{"id":"clm_EE95AAD2339E","predicate":"revenue","value":"14,202,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 14,202,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_EE95AAD2339E, https://asof.is/claim/clm_EE95AAD2339E, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm.","url":"https://asof.is/claim/clm_EE95AAD2339E","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E5421E95D3E6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/0001804220-25-000011-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-05"}},"to":{"id":"clm_E5421E95D3E6","predicate":"revenue","value":"14,342,900,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals revenue: 14,342,900,000 United States dollar\", as of 2025-12-31. Claim clm_E5421E95D3E6, https://asof.is/claim/clm_E5421E95D3E6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm.","url":"https://asof.is/claim/clm_E5421E95D3E6","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/0000872589-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-04"}}}],"rule":"Two states compared by claim id: in both, unchanged; only on to, added; only on from, ended. An ended and an added claim on one predicate are a replacement when the ended one points to the added (superseded_by), or the predicate has exactly one of each and the added begins the day the ended ends. Added rows are labelled for to, ended rows for from. Posts and Hugging Face repos are counted in skipped_posts, not listed.","legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"page-read":"its source page states the value and the date","sec-filing":"parsed from the SEC filing"}}}